Regeneron Pharmaceuticals (NASDAQ:REGN) Director Christine Poon Sells 7,830 Shares of Company Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Christine Poon sold 7,830 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $969.09, for a total value of $7,587,974.70. Following the completion of the transaction, the director owned 5,219 shares of the company’s stock, valued at approximately $5,057,680.71. The trade was a 60.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $930.67 on Thursday. The firm’s 50 day moving average price is $800.69 and its 200-day moving average price is $741.11. The company has a quick ratio of 3.66, a current ratio of 3.35 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $95.82 billion, a PE ratio of 20.55, a price-to-earnings-growth ratio of 1.45 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a twelve month low of $591.52 and a twelve month high of $991.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. The company had revenue of $5.12 billion for the quarter, compared to analysts’ expectations of $4.58 billion. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. Regeneron Pharmaceuticals’s revenue for the quarter was up 36.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $11.83 EPS. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 51.64 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Friday, November 20th. Regeneron Pharmaceuticals’s payout ratio is 8.30%.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Western Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at about $26,000. Armstrong Advisory Group Inc. grew its position in Regeneron Pharmaceuticals by 466.7% during the third quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 28 shares during the period. Activest Wealth Management grew its position in Regeneron Pharmaceuticals by 780.0% during the third quarter. Activest Wealth Management now owns 44 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 39 shares during the period. Alpine Bank Wealth Management purchased a new position in Regeneron Pharmaceuticals in the third quarter valued at about $34,000. Finally, Mowery & Schoenfeld Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals in the second quarter valued at about $29,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Bank of America added REGN to its Value 10 list, a favorable signal about the stock’s value appeal. BofA adds REGN to Value 10 list
• Positive Sentiment: Recent analyst coverage points to higher price targets and expectations for appreciation. Separately, Zacks said solid earnings-estimate revisions could help the shares continue gaining. These views follow Regeneron’s recent quarterly results, which beat consensus on earnings and revenue. RBC raises Regeneron price target Zacks on earnings estimate revisions
• Negative Sentiment: Recent disclosures show EVP Joseph Larosa sold 4,466 shares and director Christine Poon sold 7,830 shares on November 2; Poon’s sale cut her direct holding by 60%. Director Kathryn Guarini also sold 400 shares under a pre-arranged trading plan. The larger transactions could raise concerns about insider sentiment, though sales alone do not indicate a change in the company’s business outlook. Larosa sale filing Poon sale filing Guarini sale filing

Analyst Upgrades and Downgrades

REGN has been the topic of a number of research reports. Citigroup raised their target price on shares of Regeneron Pharmaceuticals from $740.00 to $825.00 and gave the stock a “neutral” rating in a research report on Friday, October 30th. Guggenheim raised their target price on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,100.00 and gave the company a “buy” rating in a research report on Monday. Canaccord Genuity Group lifted their price target on Regeneron Pharmaceuticals from $875.00 to $922.00 and gave the company a “buy” rating in a report on Wednesday, October 28th. HSBC boosted their target price on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. Finally, Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 20th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $898.97.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.